Golotimod (TFA)

Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) [1][2][3].

Product Specifications

CAS Number

[2828433-07-2]

Product Name Alternative

SCV 07 (TFA) ; Gamma-D-glutamyl-L-tryptophan (TFA)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Bacterial; STAT

Type

Reference compound

Related Pathways

Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/golotimod-tfa.html

Solubility

10 mM in DMSO

Smiles

O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2.OC(C(F)(F)F)=O

Molecular Formula

C18H20F3N3O7

Molecular Weight

447.36

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) . Int J Antimicrob Agents. 2008 Sep;32 (3) :262-6.|[2]Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92.|[3]Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07) . Oral Dis. 2010 Oct;16 (7) :655-60.